



**Voyxact**<sup>®</sup>  
(sibeprenlimab-szsi)  
Injection 400 mg/2 mL



# PRESCRIPTION START FORM

FOR CALIFORNIA USE ONLY

## ***From VOYXACT Prescription to Treatment: Guiding the Way***

This form serves as a prescription for VOYXACT<sup>®</sup> and marks the first step in starting the process to request and receive treatment.

### **VOYXACT Start Form Steps**

- 1** Fill out all required fields in the START form below and also make sure to include clinic notes and a copy of the insurance card (front and back).
- 2** Submit by fax to **1-877-875-1264**.
- 3** The prescription will be processed and delivered through a specialty pharmacy to the patient's address listed on the form.

### **Support Is Available**

If you have questions or need support, you can contact your dedicated Field Reimbursement Team or contact **Otsuka Patient Services** (Monday–Friday, 8 AM–8 PM ET, except holidays).

- ✓ Phone: **1-833-VOYXACT (869-9228)**
- ✓ Fax: **1-877-875-1264**
- ✓ E-prescribe to PANTHERx Rare NPI 1750843314 (PANTHERx Rare Specialty Pharmacy, 1120 Stevenson Mill Road, Suite 400, Coraopolis, PA 15108)



**We're here to support you. Scan to learn more.**

 **VOYXACThcp.com**

**Please see Important Safety Information and FULL PRESCRIBING INFORMATION and PATIENT INFORMATION.**

1

## Patient Information

\*First Name

\_\_\_\_/\_\_\_\_/\_\_\_\_

\*Date of Birth (MM/DD/YYYY)

\*Last Name

Sex:

Male  Female  Other

( )

Mobile  Home

\*Phone Number†

\*OK to leave voicemails about VOYXACT?†  Yes  No

\*Preferred Communication:  Phone  Email

Best Time to Contact:  AM  PM

Preferred Language (if not English): \_\_\_\_\_

\*Address (Not a PO Box)

\*City

\*State

\*ZIP

Email

I give permission to the following care partner to discuss my personal health information (Optional):

Care Partner Contact Name

Relationship to Patient

Phone Number†

Please see [Important Safety Information](#) and [FULL PRESCRIBING INFORMATION](#) and [PATIENT INFORMATION](#).

## Patient Consent to Enroll

- Sign up for Otsuka Patient Services.** I understand that agreeing to these services on page 10 is voluntary and that I do not need to sign up to receive treatment from my healthcare provider. I understand that a signed copy of this consent is available upon request. Such services may include but are not limited to the following:
- Help coordinate insurance coverage for, access to, and receipt of my medication
  - Communicate with me about possible financial assistance, and, if I am eligible, enroll and administer my participation in those programs
  - Communicate with me about my medication, treatment, and disease, including reminders, and other product-related information
  - Ask for feedback related to the services or my treatment experience
- You may be able to pay as little as \$0 for VOYXACT.<sup>‡</sup> I have read and agree to the VOYXACT Copay Program on page 10.** By checking this box, I am signing this consent of my own free will and I agree to the collection and use of my Personal Data for administration of the copay program as described above.
- Get access to VOYXACT educational communications. I'd like to sign up for ongoing support where I will get VOYXACT tips, resources, and reminders from Otsuka at the email address I provided above.** By checking this box, I agree to receive recurring marketing communications regarding educational events, information, and services from VOYXACT. I understand that the information I have provided will be used by Otsuka America Pharmaceutical, Inc. ("Otsuka") and its contracted service providers to contact me by email, phone, or mail with relevant information. I will have the ability to opt out from receiving Otsuka communications at any time by calling **1-833-VOYXACT (869-9228)** or by following the opt-out instruction within the communications. For additional information, see Otsuka America Pharmaceutical Privacy Policy at:  
<https://www.otsuka-us.com/oapi-and-opdc-privacy-policy>.

**Patient signature**

\_\_\_\_\_  
\*Date (MM/DD/YYYY)

<sup>‡</sup>The VOYXACT Copay Program is available only for commercially insured patients. Please see page 10 for limitations.

Please see **Important Safety Information** and **FULL PRESCRIBING INFORMATION** and **PATIENT INFORMATION**.

3

## Insurance Information

Do you have insurance coverage?  Yes  No

If Yes:  I have included a copy of the front and back of my insurance cards.

\*If you have insurance coverage, please check which type:

Commercial  Government

\_\_\_\_\_  
\*Prescription Benefit Insurance Name

\_\_\_\_\_  
\*Phone Number

\_\_\_\_\_  
\*Policy ID #

\_\_\_\_\_  
\*Rx Group #

\_\_\_\_\_  
\*BIN

\_\_\_\_\_  
\*PCN

\_\_\_\_\_  
\*Policyholder Name

\_\_\_\_/\_\_\_\_/\_\_\_\_\_  
\*Policyholder Date of Birth  
(MM/DD/YYYY)

Please see [Important Safety Information](#) and [FULL PRESCRIBING INFORMATION](#) and [PATIENT INFORMATION](#).

## HIPAA Authorization

I authorize PANTHERx Rare, my healthcare provider, and their business associates as necessary to disclose my Protected Health Information (PHI) as that term is defined under HIPAA, including PHI relating to my insurance benefits, medical condition, treatment, and prescription details to Otsuka and its affiliates, business partners, vendors, and other agents (Otsuka) so they can provide me with patient support services (the “Services”) for which I am eligible. Once I authorize disclosure of my PHI, it may no longer be protected by federal health privacy law and applicable state laws.

I understand that PANTHERx Rare may receive payment from the Program for providing the Services outlined in this authorization.

My PHI includes:

- My name, address, and contact information provided on this form
- Any additional information about me, my treatment and health conditions, as provided by my doctor in order to enroll me in the Otsuka Patient Services program, and any other health information that my doctor may share with Otsuka in order for me to receive the patient support services
- Payer-related information received from my health insurer
- Prescription, fulfillment, shipment, and other information provided by pharmacies or other sites of care

I understand and agree that Otsuka may combine PHI collected from me with information about me collected from other sources and use that combined information to administer the Services. Otsuka may tokenize, aggregate, and de-identify my PHI and combine that de-identified PHI with other information, as long as the combined data remains de-identified in accordance with HIPAA standards (ie, an expert has opined that it cannot be used to identify me).

This HIPAA Authorization will expire 5 years after I sign it, unless I withdraw or cancel it sooner. If I cancel this HIPAA authorization, I may no longer qualify for Services from Otsuka, but it will not impact my Provider’s treatment or my insurance benefits. I understand that this will not affect any uses or disclosures Otsuka has already acted in reliance on this authorization prior to the date this cancellation is received.

I understand that I do not have to sign this HIPAA Authorization to get my medication or insurance coverage, that I have a right to a copy, and that I can cancel this Authorization at any time by writing to:

**PANTHERx Rare Specialty LLC, 121 Bayer Road, Building 5, Pittsburgh, PA 15205.**

**Patient signature**

\_\_\_\_\_  
\*Date (MM/DD/YYYY)

\_\_\_\_\_  
\*Patient Name

\_\_\_\_/\_\_\_\_/\_\_\_\_\_  
\*Patient Date of Birth (MM/DD/YYYY)

\*Required fields.

5

## Prescriber Information

\*First Name

\*Last Name

\*Primary Specialty

\*Address

\*Practice Name

\*City

\*State

\*ZIP

\*Practice Phone Number

\*Prescriber NPI

\*Practice Fax Number

Practice Contact Name

Practice Contact Phone Number

Practice Contact Email

Please see [Important Safety Information](#) and [FULL PRESCRIBING INFORMATION](#) and [PATIENT INFORMATION](#).

6

## Primary Diagnosis Code & Clinical Information

**\*Select an appropriate diagnosis code for recurrent and persistent IgA Nephropathy (IgAN):**

- N02.B1 (with glomerular lesion)       N02.B2 (with focal and segmental glomerular lesion)       N02.B3 (with diffuse membranoproliferative glomerulonephritis)       N02.B4 (with diffuse membranous glomerulonephritis)
- N02.B5 (with diffuse mesangial proliferative glomerulonephritis)       N02.B6 (with diffuse mesangiocapillary glomerulonephritis)       N02.B9 Other recurrent and persistent IgAN       Other: \_\_\_\_\_

**\*Has the patient had a kidney biopsy?**  Yes  No

**If yes, date of kidney biopsy or write N/A:** \_\_\_\_\_

**\*uPCR (g/g) or proteinuria (g/day) or write N/A:** \_\_\_\_\_

**\*eGFR (mL/min/1.73m<sup>2</sup>) or write N/A:** \_\_\_\_\_

**\*Please list the patient's current and previous IgAN treatment(s) and dates (MM/DD/YYYY):**

\_\_\_\_\_

**\*Is there any reason the patient was not a candidate for specific treatments for IgAN? (if applicable):**

\_\_\_\_\_

**\*Known drug allergies:**

Yes If yes, please list medication(s) and associated reaction(s):

\_\_\_\_\_

No known drug allergies

Please see **Important Safety Information** and **FULL PRESCRIBING INFORMATION** and **PATIENT INFORMATION**.

\*Required fields.

\_\_\_\_\_  
\*Patient Name

\_\_\_\_/\_\_\_\_/\_\_\_\_\_  
\*Patient Date of Birth (MM/DD/YYYY)

7 **\*Prescription Information**

Please submit prescriptions by eScript if mandated by individual state laws. The prescriber must comply with state laws regarding e-prescribing, state-specific prescription form, or written prescription. Provide eScript to PANTHERx Rare by searching NPI 1750843314.

**Dispense VOYXACT 400 mg/2 mL Prefilled Syringe: Injected subcutaneously once every 4 weeks.**

**11 refills, or \_\_\_\_\_ refills**

**If eligible, I approve dispensing the Bridge Program<sup>§</sup>:**  Yes  No

8 **\*Prescriber Authorization**

I certify that I am the healthcare professional who has prescribed the therapy identified in this form. I further certify that I have made an independent judgment that the above therapy is medically necessary, and that the information provided in this form is accurate to the best of my knowledge. I attest that I am not on the HHS/OIG List of Excluded Individuals and Entities and that I am presently authorized under state law to prescribe this medication. I authorize Otsuka, and its affiliates, agents, representatives, and service providers, to act on my behalf for the purposes of transmitting this prescription to the appropriate pharmacy.

**\*Prescriber signature required** \_\_\_\_\_

**\*Date (MM/DD/YYYY)** \_\_\_\_\_

<sup>§</sup>The Bridge Program is for a limited supply of VOYXACT at no cost and is available only for commercially insured patients who are experiencing a delay in insurance coverage. Please see page 10 for terms and conditions.

**Please see [Important Safety Information](#) and [FULL PRESCRIBING INFORMATION](#) and [PATIENT INFORMATION](#).**

## Patient Consent to Otsuka Patient Services program

I consent to enrolling in the Otsuka Patient Services program. I hereby authorize Otsuka and its affiliates, business partners, vendors and other agents (collectively, “Otsuka”), to provide me with the patient support services for which I am eligible under this program. Such services may include but are not limited to assistance in obtaining approval for my prescription from my health insurance plan, emails relating to my prescription medication, including refill reminders, copay assistance if I am eligible, information about other financial assistance support, and other support services offered now or in the future. As part of the program’s offerings, I agree to my enrollment in the assistance program if I am eligible.

I agree that Otsuka may send me information about the program, including disease state and medical education materials, via email to the email address I provided, even though email is not a secure method for transmission of confidential personal information. I acknowledge and agree that Otsuka may process my personal information in accordance with its privacy policy, which is found here: <https://www.otsuka-us.com/privacy-policy>.

I hereby expressly consent to the processing of my sensitive health information by Otsuka as necessary in order to provide me with the patient support services.

I understand that Otsuka Patient Services may use and share with my healthcare providers, pharmacies, and health insurance plans, my sensitive personal information in order to provide me with services under the program, administering the program, or as otherwise required for Otsuka to meet its legal obligations.

I understand that I may be requested to provide my written consent on an annual basis by the Otsuka Patient Services program in order to continue to provide me with patient support. I understand that my pharmacy may receive payment from the program for providing the support services outlined in this consent as authorized in this consent.

I understand that I have the ability to opt out from receiving Otsuka communications at any time by calling **1-833-VOYXACT (869-9228)** or by following the opt-out instruction within the communications. For additional information, see Otsuka America Pharmaceutical Privacy Policy at: <https://www.otsuka-us.com/oapi-and-opdc-privacy-policy>.

By signing the Consent Form on page 3, I agree that Otsuka may contact my caregiver listed on the form and share my sensitive health information with my caregiver for the purpose of providing me with the patient support services.

Please see **Important Safety Information** and **FULL PRESCRIBING INFORMATION** and **PATIENT INFORMATION**.

†**Otsuka Patient Services may call you at the numbers provided for nonmarketing purposes** (eg, to help you access and start on VOYXACT). Calls may be autodialed. You may change your preferences at any time by calling **1-833-VOYXACT (833-869-9228)**.

‡**Limitations Apply for the VOYXACT Copay Program.** Valid only for those with commercial insurance and if the coverage does not cover the full cost of the VOYXACT prescription. Benefit amount is subject to a (1) monthly maximum based on typical insurance reimbursement rates, including maximum annual out-of-pocket limits established by the Affordable Care Act, and (2) a separate annual maximum benefit of the Affordable Care Act Maximum out-of-pocket amount up to \$10,600. Maximum benefits and copay assistance redemption methods may vary as necessary to ensure compliance with these Terms and Conditions. Other restrictions may apply. The VOYXACT Copay Program is not valid under any state or federal healthcare program, including but not limited to Medicare Part D, Medicaid (including Medicaid managed care), Medigap, Veterans Affairs (VA), or Department of Defense or TRICARE programs. No purchase is necessary. Patients must be 18 years and older and a resident of the United States or Puerto Rico and the patient's prescription is consistent with the FDA-approved labeling. Patients must enroll in the program without the help of any insurer, pharmacy benefit manager, or agent to these entities. Specialty pharmacy assistant enrollment is permitted. The VOYXACT Copay Program is not valid where it is prohibited by law and may not be combined with any third-party rebate, coupon, or offer. Otsuka reserves the right to rescind, revoke, or amend the program and discontinue support at any time without notice.

§**The VOYXACT Bridge Program** is not health insurance and is available for eligible, commercially insured patients only. Offer is only available to patients who have been diagnosed with an FDA-approved indication for VOYXACT. No claim for reimbursement for product dispensed pursuant to this offer may be submitted to any third-party payer, additional insurer, or a patient's state-sponsored commercial insurance. Not available to patients covered by a state or federal healthcare program, including, but not limited to, Medicare Part D, Medicaid (including Medicaid managed care), Medigap, Veterans Affairs (VA), or Department of Defense (DOD) TRICARE programs. VOYXACT Bridge Program may be dispensed after primary coverage has been attempted and the patient is experiencing a delay in coverage. Available in a 28-day supply. Refills are subject to limitations. To be eligible for an additional 28-day refill, the patient must be actively pursuing coverage through their insurance. The VOYXACT Bridge Program for VOYXACT is limited to three 28-day dispenses of VOYXACT for patients experiencing a coverage delay. Dispensing of VOYXACT, pursuant to this program, is at the sole discretion of Otsuka. This VOYXACT Bridge Program offer does not require, nor will be made contingent on, purchase requirements of any kind. Otsuka reserves the right to amend, rescind, or discontinue this program at any time without notification. Offer good only in the United States and Puerto Rico. Prescription must be provided by a healthcare provider licensed in the United States or Puerto Rico. Additional eligibility criteria may apply.

Please see **Important Safety Information** and **FULL PRESCRIBING INFORMATION** and **PATIENT INFORMATION**.

## INDICATION

VOYXACT is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.

This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether VOYXACT slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

## IMPORTANT SAFETY INFORMATION

### CONTRAINDICATION

VOYXACT is contraindicated in patients with serious hypersensitivity to sibeprenlimab-szsi or any of the excipients of VOYXACT.

### WARNINGS AND PRECAUTIONS

**Immunosuppression and Increased Risk of Infections:** VOYXACT suppresses the immune system by reducing antibody production, which may increase the risk of infections. Patients with chronic or recurring infections may have an increased risk of serious infection. In clinical trials, infections occurred in 49% of patients treated with VOYXACT compared with 45% of patients treated with placebo.

Before initiating VOYXACT, assess patients for active infections. During treatment, monitor patients for signs and symptoms of infection. If a serious infection develops, consider interrupting VOYXACT until the infection is controlled.

**Immunosuppression and Immunization Risks:** Because of its mechanism of action, VOYXACT may interfere with immune responses to vaccines and increase the risk of infection from live vaccines. Live vaccines are not recommended within 30 days prior to initiation of VOYXACT or during treatment with VOYXACT as safety has not been established. No data are available on the secondary transmission of infection from persons receiving live vaccines to patients receiving VOYXACT or on the efficacy of immunizations administered while receiving VOYXACT.

**Common Adverse Reactions:** The most common adverse reactions (reported in  $\geq 10\%$  of patients treated with VOYXACT and at a higher incidence than placebo) in patients treated with VOYXACT and placebo, respectively, were infections (49% versus 45%) and injection site reactions (24% versus 23%). The most common infection was upper respiratory infection (15% versus 14%), and the most common injection site reaction was injection site erythema (13% versus 12%). Most adverse reactions were reported as mild or moderate in severity and resolved without treatment interruption or discontinuation.

Please see **Important Safety Information** and **FULL PRESCRIBING INFORMATION** and **PATIENT INFORMATION**.

## IMPORTANT SAFETY INFORMATION (cont'd)

### WARNINGS AND PRECAUTIONS (cont'd)

**Pregnancy:** There are no available data on VOYXACT use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. Monoclonal antibodies, such as sibeprenlimab-szsi, can be actively transported across the placenta as pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimester of pregnancy.

**Lactation:** There are no data on the presence of sibeprenlimab-szsi in human milk, the effects of sibeprenlimab-szsi on the breastfed infant, or the effects of sibeprenlimab-szsi on milk production.

**Pediatric Use:** Safety and effectiveness of VOYXACT in pediatric patients have not been established.

**Geriatric Use:** Clinical studies of VOYXACT did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger adult patients.

Pregnant women exposed to VOYXACT, or their healthcare providers, should report VOYXACT exposure by calling **1-833-869-9228** or visiting [www.VOYXACT.com](http://www.VOYXACT.com)

To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at **1-800-438-9927** or FDA at **1-800-FDA-1088** ([www.fda.gov/medwatch](http://www.fda.gov/medwatch)).

Please see **FULL PRESCRIBING INFORMATION** and **PATIENT INFORMATION**.